• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    NKGen Biotech, Inc. - Common Stock (NQ: NKGN )

    0.2470 -0.0130 (-5.00%)
    Streaming Delayed Price Updated: 3:59 PM EST, Nov 13, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 659,815
    Open 0.2650
    Bid (Size) 0.2470 (84)
    Ask (Size) 0.2500 (1)
    Prev. Close 0.2600
    Today's Range 0.2320 - 0.2700
    52wk Range 0.2026 - 4.060
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
    From NKGen Biotech
    Via GlobeNewswire
    Why Spirit Airlines Shares Are Trading Higher By Around 44%; Here Are 20 Stocks Moving Premarket
    Via Benzinga

    Performance

    YTD
    -91.85%
    -91.85%
    1 Month
    +0.37%
    +0.37%
    3 Month
    -72.59%
    -72.59%
    6 Month
    -78.33%
    -78.33%
    1 Year
    -91.36%
    -91.36%

    More News

    Read More
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Dow Falls Over 100 Points; Netflix Posts Upbeat Results
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    Why Intuitive Surgical Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    NKGen Biotech Announces Upcoming Presentation at the 16th World Stroke Congress (WSC 2024)
    From NKGen Biotech
    Via GlobeNewswire
    NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
    From NKGen Biotech
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    NKGen Biotech’s Positive Phase 1 Clinical Data in Moderate Alzheimer’s Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a Trial
    From NKGen Biotech
    Via GlobeNewswire
    NKGen Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference
    From NKGen Biotech
    Via GlobeNewswire
    NKGen Biotech Receives Notification From Nasdaq Related to Delayed Quarterly Report
    From NKGen Biotech, Inc.
    Via GlobeNewswire
    NKGen Biotech Presents New Positive SNK01 Biomarker Data at the 2024 Alzheimer’s Association International Conference
    From NKGen Biotech
    Via GlobeNewswire
    Why Tellurian Shares Are Trading Higher By Around 65%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Why Domino's Pizza Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    Barclays Just Raised Its Price Target on Intuitive Surgical (ISRG) Stock
    Via InvestorPlace
    WBD Stock Pops as Warner Bros. Considers Streaming Spinoff
    Via InvestorPlace
    Why Is NKGen Biotech (NKGN) Stock Up 18% Today?
    Via InvestorPlace
    Why NKGen Biotech (NKGN) Stock Is Skyrocketing
    Via Benzinga
    NKGen Biotech to Present New Positive SNK01 Clinical Trial Biomarker Data at the 2024 Alzheimer’s Association International Conference
    From NKGen Biotech
    Via GlobeNewswire
    NKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors
    From NKGen Biotech
    Via GlobeNewswire
    NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
    From NKGen Biotech
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.